All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...781Next →

hiv & aids news selected from other sources

  • PrEP
    Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots
    NATAP | 1 hour ago

    One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would "definitely switch" to a long-acting PrEP shot every 3 months, while another third would "probably switch," according to results of a 90-man survey. Hispanic and nonwhite men were significantly more likely to be among definite switchers.

  • PrEP
    More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'
    Medscape (requires free registration) | 2 hours ago

    The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.

  • Tuberculosis and HIV
    2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
    Treatment Action Group | 6 hours ago

    Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose.

  • Drug-resistant TB
    Access: MSF reports on use of the new tuberculosis drugs bedaquiline and delamanid
    - Médecins Sans Frontières (MSF) International | 6 hours ago

    Access to the new tuberculosis (TB) drugs remains severely limited worldwide, but MSF hopes its experience can inform and encourage wider use, while needed clinical research continues.

  • Epidemiology
    STD rates sharply rise in U.S. says CDC – Will misinformation from PrEP critics prevail?
    Project Inform | 18 hours ago

    The Centers for Disease Control and Prevention (CDC) just published a report on the rates of chlamydia, gonorrhea and syphilis in 2015, finding the highest number of case reports on these infections in 20 years and a steep increase over the last reported period in 2014. Is this a cause for concern? Absolutely. But, as will inevitably be the case, there are going to be questions about whether increasing use of pre-exposure prophylaxis (PrEP) is to blame and the answer is pretty conclusively “no” as far as one can tell from the available data and the CDC as much as says so.

  • Circumcision
    HIVR4P 2016: Circumcision offers major contribution to ending HIV epidemic as a public health threat
    Science Speaks | 25 October 2016

    Kenya’s medical circumcision program launched early with ambition, charting circumcisions performed for 1.3 million men by the end of 2015, leaving evaluators asking what is and what will be the impact of this HIV prevention intervention on the epidemic?

  • PrEP
    First year Amsterdam PrEP project complete
    GGD Amsterdam | 24 October 2016

    Last year the Public Health Service of Amsterdam (GGD) started the Amsterdam PrEP project, a research project focused on the applicability of PrEP for HIV prevention among men who have sex with men (MSM) and transgender individuals. We now have a picture of the first 200 participants and of national developments over the past year. Almost three-quarters of participants preferred daily PrEP to event-based use (before and after sex). PrEP protected almost all participants from HIV. Two participants contracted an HIV infection in the past year. (To read the press release in English, click the link on the right-hand side of the page).

  • PrEP
    Report recommends PrEP for use in Scotland
    HIV Scotland | 24 October 2016

    Last week, a report recommending PrEP for use in Scotland was endorsed by the Executive Leads Network, who govern Scotland's Sexual Health and Blood Borne Virus Framework. The report was written by the Scottish HIV PrEP Short Life Working Group (SLWG), administered by HIV Scotland and chaired by Dr Rak Nandwani.

  • New and experimental HIV treatments
    New nanomedicine approach aims to improve HIV drug therapies
    Science Daily | 24 October 2016

    New research led by the University of Liverpool aims to improve the administration and availability of drug therapies to HIV patients through the use of nanotechnology.

  • Hepatitis C treatment
    A promising Hep C program seems to be working — and it could be a model for other countries
    Business Insider | 24 October 2016

    Georgia, a country nestled against the Black Sea between Turkey and Russia with a population of 3.7 million, has since taken on a public health effort to help reduce its prevalence of hepatitis C (HCV for short) by 90% by 2020.

← First12345...1246Next →

Conference news

Latest news from the HIV Research For Prevention (R4P) conference.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Achieving the 90-90-90 target

With advances in HIV testing, treatment and care, some countries are making great progress towards the UNAIDS 90-90-90 target.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap